BNOXBIONOMICS LIMITED/FI

Nasdaq bionomics.com.au


$ 0.69 $ 0.02 (2.36 %)    

Friday, 05-Jul-2024 15:54:06 EDT
QQQ $ 495.80 $ 5.12 (1.04 %)
DIA $ 393.71 $ 0.87 (0.22 %)
SPY $ 554.29 $ 3.18 (0.58 %)
TLT $ 92.56 $ 0.76 (0.83 %)
GLD $ 220.89 $ 2.94 (1.35 %)
$ 0.6818
$ 0.71
$ 0.60 x 200
$ 0.72 x 100
$ 0.68 - $ 0.71
$ 0.65 - $ 6.41
75,890
na
1.01B
$ 0.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bionomics-files-for-resale-of-up-to-364b-ordinary-shares-by-the-selling-shareholder

- SEC Filing 

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-reveals-detailed-data-from-ptsd-trial-stock-soars

Bionomics' Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, c...

 bionomics-provided-a-2023-review-and-its-outlook-for-2024

Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-trau...

 hc-wainwright--co-reiterates-buy-on-bionomics-maintains-8-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Bionomics (NASDAQ:BNOX) with a Buy and maintains $8 price target.

 bionomics-presents-detailed-data-on-the-validity-and-reliability-of-the-subjective-units-of-distress-scale-at-the-2023-american-college-of-neuropsychopharmacology-annual-meeting

A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and re...

 bionomics-has-been-granted-european-patent-ep3867252-titled-6-indan-2-yloxy-3-morpholine-4-carbonyl-18-naphthyridin-4-one-derivatives--similar-compounds-as-modulators-of-the-alpha-7-nicotinic-acetylcholine-receptor-for-the-treatment-of-anxiety

https://register.epo.org/application?number=EP19873627

 bionomics-meets-the-fda-lead-drug-candidate-for-social-anxiety-heads-to-phase-3

Biopharma company Bionomics Ltd.

 bionomics-announced-the-outcomes-of-an-end-of-phase-2-meeting-with-the-fda-for-bnc210-for-the-acute-treatment-of-social-anxiety-disorder-into-phase-3-studies-first-patient-dosing-in-phase-3-program-planed-for-q1-fy24---8k

https://www.benzinga.com/secfilings/23/10/35261568/bionomics-limitedfi-general-corporate-statement-by-foreign-issuer-form6